Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| 37% sequential growth in SKYTROFA revenue from Q3 to Q4 was again driven primarily by strong underlying demand in the US |
| Both TransCon IL-2 β/γ and TransCon TLR7/8 Agonist has shown favorable safety profiles and single-agent clinical activity |
| We feel pretty confident we will do the optimum where we see the fastest, best way to come out to the patient and we create most value for Ascendis shareholders |
| And we were very, very, very successful to that |
| We believe Ascendis is advancing to become a leading biopharma company with a strong focus on endocrinology rare diseases and capabilities to also create value in other therapeutic areas as we're doing in oncology, ophthalmology, and metabolic diseases |
| Because of the decisions we took in 2023, we believe Ascendis is a leaner, more efficient organization in 2024, well-positioned to fulfill Vision 2030 with three independent endocrinology rare disease blockbuster products and expand our engine for future innovation |
| With SKYTROFA expanding the US growth hormone market to the potential of $3 billion, we believe SKYTROFA has the potential to be a blockbuster on US revenue alone |
| By addressing the needs of the patients, caregivers, physicians, and payers, SKYTROFA achieved US market value leadership in 2023, just two years after launch |
| We are pleased with the interest in our once-monthly GPL-1 program and from our platform technologies, we expect to continue to generate many more opportunities in the future |
| Because these two companies that is providing them the key element where we have seen them taking market is basically taking their own product, their own product on the daily growth hormone class and then transform over to the long-acting where we take it from everywhere because our improved treatment outcome |
| The benefit with TransCon PTH after a few weeks, they will receive a benefit |
| And I think it's a really, really interesting perspective at base you could see growth hormone treatment because that is really where the benefit of growth hormone is that it really can build up the muscle mass in a much more stronger mass in a very, very normalized manner |
| We know how we really are providing a treatment that really are providing a meaningful differentiation for the patient, both on short-term and really also are helping in eliminating the long-term risk of the disease |
| As presented at the JPMorgan Conference in January, we showed significant improvement in health and quality of life for children with achondroplasia treated with TransCon CNP compared to placebo |
| You saw our differentiation in ophthalmology, we made cost has been our company, and we really feel that they are really in an optimal value both to create value and really help the patient in this area |
| In the open-label extension, we observed unexpected strong patient retention of 97% for now up to four years |
| We expect 2024 to be an extremely important year for oncology pipeline with data readout in well-defined patient population in the fourth quarter |
| YORVIPATH Europe Direct launch is off to a great start with our first prescription and orders perceived at the first day of launch, demonstrating the severeness of the disease and the unmet medical need |
| We continue making significant progress towards our financial goal of becoming operating cash flow breakeven on a quarterly basis by the end of 2024 |
| Our strategic roadmap to achieve blockbuster status for each of our three endocrinology rare disease products and expand our engine for future innovation |
| So, as you saw here in the Q4, we're realizing now the benefits of the streamlined operational changes and processes that Jan has talked about with OpEx going down to about €155 mi total |
| So for us, the bearer for medical exception is just improving |
| We always see the benefit of physician really getting the benefit seen in their own eyes that take patients, take them on treating typical two to five really to see how the product function |
| So, the launch, we really look forward to provide much better update when we come to Q1, much better after Q2 and much, much better again after Q3 |
| I can be bullish now and saying in the years that all patients in Germany that have hypoparathyroidism should be on treatment |
| And I believe that taking all this aspect into it, we will find benefit that never had been seen and I hope it will both come for quality of life, body composition, physical function, and also the radiological endpoint that basically providing a different way of how we improve the texture |
| TransCon CNP dosed at 100 mg per kilo per week has demonstrated superiority compared to placebo in two 52-week trials |
| Our ability to create value in multiple therapeutic areas outside of endocrinology rare disease, our progress towards Vision 2030, and the potential success of Eyconis |
| And we will see more and more when we see more data from longer part of treatment because it takes longer time to really to see the right benefit on this or change of this proportionality, but we definitely are seeing the same positive development |
| So, for me and Ascendis, we don't see that it's really changing anything about how we are progressing to continue and build us to a blockbuster potential just in the US, and we will continue to do it because of our product strengths |
| Statement |
|---|
| Overall, our operating loss for the fourth quarter declined sequentially by 73% to €37 million from €134 million in the third quarter of 2023 |
| But if you have a child that got born and first started treatment of eight years, they still have a lack of growth |
| So therefore, in my numbers are a little bit weak in that, I would think it's about 40-60 or something like that, but I'm not 100% sure about that |
| Total operating expenses were €155 million for the fourth quarter, down 12% sequentially from the third quarter |
| Specific with the entrance of the two other long-acting the basic, the daily growth hormone is starting to disappear more and more |
| On SKYTROFA, Jan, you mentioned in the past commentary about the decreasing investment among the daily growth hormone companies and products |
| The problem is that I cannot really remember how many patients that is in Europe and US between the different trials |
| We actually believe that these two products have never proven that can show the same outcome as a normal daily growth hormone treatment that you get in the US |
| It was a hard task, not already always pleasant, probably there now |
| It's not only just losing weight |
| That is why when you think about a child with growth hormone deficiency, not have been treated for eight, nine years, starting potential treatment and then suddenly hit the parents' height as expected |
| R&D costs in the quarter totaled €90.9 million, down 18% sequentially from the third quarter of 2023, primarily driven by lower endocrinology rare disease related costs as trials and development complete and lower oncology-related costs |
| The negative part is that is you basically are in a position that you're losing a large amount of muscle mass and specific, if you're not adhere to the treatment and make period of break start-up again, period of break, you can basically be in position that when you're not taking you build up the fat faster than the muscle weight |
| This is more that the burden for this society |
| There are some people that are saying that delay data out because of medical meeting |
| When we come to the Phase III data, yes, we have a primary endpoint because that got established as a traditional way of our primary endpoint is that really an rational endpoint for achondroplasia? I have my doubt |
| And I have to think you should never consider short to be in disease |
Please consider a small donation if you think this website provides you with relevant information